The novel coronavirus pneumonia incident that started to occur in Wuhan City, Hubei Province from Dec. 2019 has produced continuous impacts on the Chinese people.
The World Health Organization (WHO) officially announced the current novel coronavirus epidemic as a "public health emergency of international concern" (PHEIC) on Jan. 30, 2020. According to the official definition of the WHO, this means that this epidemic starting in Wuhan, China has been a threat to the public health security of countries in the world and requires the joint responses of the international community.
The National Medical Products Administration of China (NMPA) and related provincial administrations have taken active response measures at the beginning of the epidemic confirmation and strict control: nearly 10 detection kits of many enterprises have so far been approved for clinical diagnosis and detection.
However, there are still no clear conclusions as to the effective drugs that people are more concerned about.
The WHO’s replies to those key issues in the related guideline are as follows:
Is there a vaccine for a novel coronavirus?
Reply: When a disease is new, there is no vaccine until one is developed. It can take a number of years for a new vaccine to be developed.
Is there a treatment for a novel coronavirus?
Reply: There is no specific treatment for disease caused by a novel coronavirus. However, many of the symptoms can be treated, therefore, treatment can be based on the patient’s clinical condition. Moreover, supportive care for infected persons can be highly effective.
To actively respond to the current predicament of lacking effective drugs, both Chinese and overseas pharmaceutical enterprises are actively screening and assessing the drugs marketed or in development, to seek effective drugs against this virus pneumonia challenge.
The latest information on the clinical trials of related drugs is collected and organized herein, in the hope of providing some help to people and pharmaceutical practitioners.
Description: The order in which the following drugs are introduced only represents the writing order in this article instead of the priorities of my recommendation of the drug efficacy.
Part I: Arbidol
1.1-Purpose of study
The purpose is to determine the effect and safety of arbidol in patients with 2019 novel coronavirus (2019-nCoV). According to the principles of randomized, double-blind, controlled clinical trials, patients with 2019-nCoV are divided into three groups, with the first group administered 200mg arbidol, tid (3 times a day), the second group administered 400mg arbidol, tid, and the third group not administered arbidol, for separately 5 days. And the three groups of patients receive other antiviral and comprehensive treatments that are the same. Then, researchers will compare the first result: 28-day mortality, and the second result: ICU length of stay, duration of mechanical ventilation, hospitalization expenses, antibiotic use cost, SOFA score, CURB-65 score, APACHE score, and other clinical indicators.
1.2-Clinical trial information points
The clinical trial indication of arbidol is 2019-nCoV, with patients divided into three groups. The trial belongs to a post-marketing phase IV clinical trial as arbidol has been marketed for years.
The clinical trial needs to recruit 500 subjects. According to the above screenshot, the research topic is a randomized, multicenter, controlled clinical trial to evaluate arbidol’s effects against 2019-nCoV infection. The trial is estimated to start on Jan. 25, 2020, preliminarily end on Apr. 30, 2020 and eventually end on May 30, 2020.
- According to the above requirements for subjects, children, adult and elderly patients of all genders can all participate in the clinical trial, however, healthy volunteers are not accepted.
- The number of the clinical trial is NCT04246242 via which all related information can be searched for. The sponsor of the clinical tri...
Read More
(All Rights Reserved)